Time to Hyperkalemia and Other Outcomes Post-Implementation of the 2021 CKD-EPI Creatinine Equation: An Observational Cohort Study
Preprint
Abstract
Background Timely diagnosis can delay progression to poor clinical outcomes and biomarker endpoints in CKD. Our objective was to analyze how the implementation of the 2021 CKD-EPI Creatinine Equation (CKD-EPI 2021) affected time to the doubling of serum creatinine, prescription or dispense of potassium-lowering drugs, hyperkalemia, and creation of arteriovenous graft fistula for dialysis within one year of CKD diagnosis. Methods We used retrospective EHR data to create two cohorts of adult patients based on date of diagnosis. We followed patients from their CKD diagnosis to the occurrence of each outcome, their last medical encounter, or 1-year post diagnosis, whichever occurred first. The first cohort was diagnosed in 2021 when the CKD-EPI 2009 Creatinine Equation (pre-update cohort) was recommended. The second cohort was diagnosed in 2022 when CKD-EPI 2021 (post-update cohort) was recommended. Multivariable models for the time relationship between cohort and each outcome were adjusted for demographics, social determinants of health, and comorbidities. As CKD-EPI 2021 was race-free, we also considered the interaction between cohort and race. Results We found 261,774 patients with a first-time CKD diagnosis. After implementation of CKD-EPI 2021, patients were less likely to have a diagnosis of hyperkalemia, potassium-lowering drug prescription, a doubling of serum creatinine, or an arteriovenous graft fistula placement within a year of CKD diagnosis. Black patients in the post-update cohort were less likely to be diagnosed with hyperkalemia compared to Black patients in the pre-update cohort (AHR 0.83; CI 0.80, 0.86), but Black patients overall were significantly more likely than non-Black patients to have hyperkalemia. Conclusions Time to poor clinical outcomes and biomarkers differs by the date of CKD diagnosis. Future work should elucidate the mechanisms driving these differences, whether there have been significant changes in treatment practices since the CKD-EPI 2021 recommendation, and long-term effects of each outcome.Keywords
This publication has 37 references indexed in Scilit:
- Long-term Patiromer Use and Outcomes Among US Veterans With Hyperkalemia and CKD: A Propensity-Matched Cohort StudyKidney Medicine, 2023
- Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trialsKidney International, 2023
- Hyperkalemia: Prevalence, Predictors and Emerging TreatmentsCardiology and Therapy, 2022
- Gender Disparities in Kidney Transplantation Referral Vary by Age and Race: A Multiregional Cohort Study in the Southeast United StatesKidney International Reports, 2022
- Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practiceJournal Of Nephrology, 2018
- AKI on CKD: heightened injury, suppressed repair, and the underlying mechanismsKidney International, 2017
- Fistula First Initiative: Historical Impact on Vascular Access Practice Patterns and Influence on Future Vascular Access CareCardiovascular Engineering and Technology, 2017
- Life expectancy with chronic kidney disease: an educational reviewPediatric Nephrology, 2016
- Effect of Patiromer on Reducing Serum Potassium and Preventing Recurrent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease on Raas InhibitorsEuropean Journal of Heart Failure, 2015
- Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney DiseaseJAMA, 2015